Shares of AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) fell 3.3% during mid-day trading on Wednesday . The company traded as low as $24.60 and last traded at $24.83, with a volume of 405,507 shares trading hands. The stock had previously closed at $25.68.

A number of brokerages have issued reports on AMAG. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $37.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, May 5th. Jefferies Group reiterated a “buy” rating on shares of AMAG Pharmaceuticals in a report on Wednesday, May 4th. Raymond James Financial Inc. downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 4th. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a report on Friday, August 12th. Finally, Leerink Swann reduced their price target on shares of AMAG Pharmaceuticals from $45.00 to $40.00 and set an “outperform” rating on the stock in a report on Wednesday, May 4th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $40.60.

The stock’s market capitalization is $847.36 million. The company has a 50-day moving average price of $25.53 and a 200-day moving average price of $23.78.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.20 by $0.25. During the same period last year, the company posted $1.12 earnings per share. The firm had revenue of $127.40 million for the quarter, compared to analysts’ expectations of $128.52 million. The business’s quarterly revenue was up 46.7% on a year-over-year basis. Equities analysts predict that AMAG Pharmaceuticals Inc. will post $5.41 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the company. Bank of Montreal Can increased its position in AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock valued at $2,287,000 after buying an additional 73,152 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock valued at $1,498,000 after buying an additional 42,208 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in AMAG Pharmaceuticals by 13.9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,100 shares of the specialty pharmaceutical company’s stock valued at $5,316,000 after buying an additional 21,500 shares during the last quarter. Finally, Rhumbline Advisers increased its position in AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after buying an additional 3,420 shares during the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.